A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
Thelenota ananas; 2) depolymerizing THG to obtain dTHG by method of peroxide depolymerization or method of peroxide depolymerization catalyzed by catalyst of the fourth period transition metal ions; 3) removing impurities with lower and/or higher molecular weight in dTHG.
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
C08B 37/00 - Préparation des polysaccharides non prévus dans les groupes Leurs dérivés
Disclosed is an anhydrous crystal of letrozole. The structure and characteristics of the anhydrous letrozole crystal are characterized by X-ray powder diffraction, differential scanning calorimetry, infrared spectrum and the like. The characteristic diffraction peaks of the crystal in a powder X-ray diffraction pattern at 2 θ are 13.08±0.2, 14.06±0.2, 17.04±0.2, 21.44±0.2 and 29.24±0.2 degrees. Also disclosed are a method for preparing the anhydrous letrozole crystal by using an anhydrous and pure organic solvent as a crystallization solvent, and using the crystal in a pharmaceutical formulation for antiestrogen therapy for treating menopausal patients with advanced breast cancer.
Phenyl nitrone compounds containing stilbene segment and pharmaceutically acceptable salts thereof are provided. The above compounds can be used for treating cancer and also can be used as neuroprotective agent. Preparation method of the above compounds, pharmaceutical compositions comprising the above compounds and their use in the preparation of anti-tumor medicines are also provided.
C07C 291/02 - Composés contenant du carbone et de l'azote et comportant des groupes fonctionnels non couverts par les groupes contenant des liaisons oxyde d'azote
The invention discloses a diphenylethene derivatives with the structure shown as the formula 1 and pharmaceutically-acceptable salts thereof. Since the compounds have the property of PPAR gamma agonist, the compounds have insulin hypersensitivity and blood sugar reducing activity and can be used for preventing and treating II-type diabetes mellitus. The invention also provides the preparation methods for these compounds, pharmaceutical compositions containing the compounds and the uses of the compounds for preparing hypoglycemic drugs, wherein Z represents the formula (I) or the formula (II).
Disclosed is a depolymerized glycosaminoglycan from Thelenota ananas(dTHG), weight average molecular weight of which is about 8000 ~ 20000Da, and monosaccharide components of which are acetylgalactosamine(GalNAc), glucuronic acid(GlcUA), fucose(Fuc) or their sulfates(expressed as -OSO3-), in which molar ratio of GalNAc: GlcUA: Fuc: -OSO3- is about 1: (1±0.3 ): (1±0.3): (3.5±0.5). Said dTHG is a potent endogenous factor X enzyme inhibitor, which has good anticoagulating and antithrombotic activity, and can be used to prevent and/or treat thrombotic diseases. Also provided is a method for preparing said dTHG, which comprises steps of 1) extracting and obtaining fucosylated glycosaminoglycan(THG) from Thelenota ananas body wall; 2) depolymerizing THG to obtain dTHG by method of peroxide depolymerization or method of peroxide depolymerization catalyzed by catalyst of the fourth period transition metal ions; 3) removing oligomer and/or polymer impurities in dTHG.
Disclosed is a method for preparing depolymerized fucosylated glycosaminoglycans which are obtained by depolymerizing fucosylated glycosaminoglycans through peroxide depolymerization catalyzed by the fourth period transition metal ions in water phase medium. The depolymerized fucosylated glycosaminoglycans obtained have no less than 80% of glycan molecular number taking GaINAc as reductive terminal, and weight average molecular weight of which is about 6000Da~ 20,000Da, and PDI of which is 1.0- 2.0.
A pharmaceutical composition comprising high concentrate of polydatin. The composition contains polydatin, meglumine and/or cyclodextrin. The said composition is in the form of aqueous solution or lyophilized product which is to be prepared before using.
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61K 31/7034 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
brevets
